A Spanish trial finds similar sustained IBD clinical remission rates 1-year post-withdrawal vs maintenance of anti-TNF ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

Shortly after his diagnosis, WIlliams was in and out of the hospital every two weeks throughout the fall, until the new year.

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

Turmeric, featuring its active compound curcumin, provides powerful anti-inflammatory and antioxidant benefits. This ancient ...

The 28-year-old defender is now supporting IBD research by the Royal Devon University Healthcare NHS Foundation Trust and the ...

On a population basis, a study published this month shows prevalence is now 254.8 cases of ulcerative colitis and 77.0 cases ...

IBD is actually an immune system disorder with an unknown cause, diet can influence symptoms but not cause the disease.

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

Investing.com -- Spyre Therapeutics (NASDAQ:SYRE) stock rose 4% Friday after Deutsche Bank analyst David Hoang initiated coverage with a Buy rating and a $43 price target, suggesting significant ...

The Food and Drug Administration (FDA) has expanded the approval of Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) to include a ...

Researchers at the University of Ottawa (uOttawa) will play a central role in the development of a promising AI tool aimed at ...